SHR-1819 Injection Blank Preparation

Phase 2Small molecule

Guangdong Hengrui Pharmaceutical Co., Ltd

SHR-1819 Injection Blank Preparation is one of 45 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisRecruiting

Atopic DermatitisPhase 2

Recruiting

Competition

Competitive Landscape

116 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

1 2

Fludara

Sanofi

Phase 3

1 3

Adtralza

LEO Pharma

Phase 3

17 4

Amlitelimab

Sanofi

Phase 3

2 5

Certolizumab

Johnson & Johnson

Phase 3

1 6

DUPIXENT

Regeneron

Phase 3

1 7

ICP-332

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

2 8

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

5 9

MG-K10

SShanghai Mabgeek Biotech.Co.Ltd

Phase 3

2 10

LNK01001

LLynk Pharmaceuticals Co., Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Atopic Dermatitis

NCT07321951

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

Recruiting· Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07321951·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SHR-1819 Injection Blank Preparation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-1819 Injection Blank Preparation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-1819 Injection Blank Preparation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Hengrui Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Guangdong Hengrui Pharmaceutical Co., Ltd

SHR-1819 Injection Blank Preparation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News